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Antimicrobial stewardship (AMS) has been touted as one of the key strategies required
in tackling worldwide escalation of antibiotic resistance. Although AMS has optimized
antibiotic usage and reduced the incidence of resistance development in some regions,
its full global potential has been curtailed by various AMS-impeding factors. This
article seeks to highlight in a detailed perspective, the key challenges that hamper
global AMS endeavors, some of which include the paucity of effective implementation
strategies that cater for the challenging settings of developing nations, the slow
response of governments, uncoordinated AMS activities as well as implementation
fragmentation across different sectors and countries. The authors of this article call
upon all stakeholders to pay attention to these seemingly obvious but often under-
addressed problems. If left unresolved, this may render all current and future AMS
initiatives pointless.
Keywords: antimicrobial stewardship, antibiotic resistance, implementation challenges, global framework, action
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INTRODUCTION
The worldwide escalation in antibiotic resistance has sparked fear of a looming post-antibiotic
era (WHO, 2014). Such a global health crisis would render even common infections untreatable
with the current cocktail of antibiotics available. With the recent discovery by Chinese scientists
of a strain of Escherichia coli in local livestock resistant to the last resort antibiotic colistin, the
prediction of an antibiotic apocalypse is somewhat reaffirmed (Liu et al., 2016). Of greater concern
is the speed of trans border spread of such resistance which was reported in Europe only several
months ago and has since reached the US (Spencer, 2015; Christensen, 2016). The worrying spread
of drug-resistant infections is causing 700,000 deaths annually at present and if left unaddressed,
it is projected to cause 10 million lives per year by 2050 with a cumulative economic cost of
100 trillion USD (O’Neill, 2016). The advocacy of rational use of antibiotics began forthwith the
recognition of their inappropriate use being the key driver of resistance development (Goldmann
and Huskins, 1997; WHO, 2002; Hashemi et al., 2013). As such, Antimicrobial stewardship (AMS)
has emerged as one of the key strategies employed to minimize the development of resistance
in order to preserve antibiotic efficacy in the light of dwindling antibiotic candidates in the
pipeline. AMS-guided interventions have optimized antibiotic usage, reduced the incidence of
resistance development and improved clinical outcomes in hospital inpatient settings as reported
by the Cochrane Reviews (Davey et al., 2013). Nevertheless, it remains challenging to gauge the
achievements of AMS from an international perspective since the global surveillance data pre- and
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post–AMS programs implementation are limited and the level
of surveillance undertaken varies across different regions (WHO,
2015). Unfortunately, it is evident at present that the worldwide
rate of antibiotic resistance development has shown no sign
of slowing down whilst the global consumption of antibiotics
continues to rise over the years (Boeckel et al., 2014; WHO,
2014). So what exactly did we miss? A closer look at the key
problems plaguing current AMS initiatives can spur more ideas
to further refine feasibility of AMS alongside the novel solutions
proposed by many thus far, particularly in terms of improving
the implementation aspects on a global scale. This article seeks
to illustrate in a detailed perspective, the main implementation-
impeding challenges which have curtailed the full potential of
AMS. The authors of this article are aware that there may not
be straightforward solutions to these issues although we strongly
believe that improvements are attainable through progressive
changes if these aspects are given due consideration in all
proposed AMS plans in the future.
Resources Limited Environments of
Developing Nations
The AMS programs are a heterogeneous mix of system-
and organizational-based interventions espoused internationally
to address the antibiotic resistance epidemic (Doron and
Davidson, 2011; NHS, 2015). Despite the numerous strategies
set forth in AMS programs to contain the spread of resistance,
there is unlikely a single ‘perfect’ approach in ensuring their
implementation across the board, more so within the resource-
poor environment of low- and middle- income countries
(LMICs). The low level of political commitment to the cause
of AMS owing primarily to the scarcity of AMS funding as
well as the dearth of expertise in orchestrating AMS initiatives,
are some of the biggest hurdles to AMS adoption among these
countries (Kimang’a, 2012; Wertheim et al., 2013; Huttner et al.,
2014; WHO, 2015). Such aspects remain under-addressed even
with the recognition of these being the critical pre-requisites
for effective AMS activities. In this context, LMICs are faced
with the irony of few and/or defunct AMS programs despite
being the hotspots for infectious diseases and antimicrobial
resistance.
In Africa for instance, an international survey revealed the
presence of AMS programs in only 14% of hospitals hence
the lowest prevalence in comparison to all other regions
(Huttner et al., 2014; Mendelson and Matsoso, 2015). This
is further compounded by the fact that, most countries
in the sub-saharan Africa have yet to implement any of
the recommended interventions for resistance containment
due to various economic and healthcare challenges (Okeke
et al., 2007; Kimang’a, 2012). With this continent already
confronting an overwhelming burden of communicable diseases
(such as malaria, tuberculosis, and AIDS) while grappling
with limited choice of quality antimicrobials for infection
treatments, it is of little surprise that AMS has not been
prioritized (Okeke et al., 2007). Surveillance has also been
made difficult due to a combination of factors such as
inadequate number of trained personnel and properly equipped
laboratories (Kimang’a, 2012). This has hampered infection
control/prevention endeavors that are already inadequate to
begin with. The lack of clinical/epidemiological data has rendered
the efforts to identify the pattern of resistance development
and trend of spread futile hence complicates the devising
of appropriately targeted interventions based on situational
analysis.
AMS at Odds with Healthcare Systems
and Local Policies among the Emerging
Economies
More pertinently, global AMS initiatives are simply incompatible
with the less-refined healthcare systems and practices of many
countries. Among the emerging economies, the accessibility
to healthcare and pharmaceuticals has improved in tandem
with economic progress with the caveat of high prevalence of
inappropriate antibiotic use. This is evident from a recent study
which revealed the high rates of antibiotic prescribing in the
primary care settings of Malaysia even for self-limiting conditions
(Rahman et al., 2016). Similarly, antibiotic dispensing without
prescription/medical consultation is also a common practice as
can be seen in countries like China, Chile, Malaysia, and Vietnam
(Nguyen et al., 2013; Tiong et al., 2016). Self-medication is
rampant, often being dubbed the most affordable and convenient
mode of treatment (Nguyen et al., 2013; Huttner et al., 2014;
Tiong et al., 2016). There is also demand for drugs such as
antibiotics from the gray market, driven primarily by their
cheaper prices, and in part by the poor regulatory enforcement.
The risk of resistance due to irrational antibiotic use is further
augmented by the consumption of counterfeit antibiotics with
dubious pharmacokinetics profile since sup-optimal dosing is
a prevalent cause for breeding human reservoirs of resistant
pathogens (Bate et al., 2013). This has proved to be problematic
in some parts of Africa, Asia, and Latin America where up to
30% of medicine on sales are counterfeit, exacerbated by the
high frequency of incomplete antibiotic course among the lower
income group whose antibiotic consumptions are for the purpose
of symptomatic relief instead of microbial eradication (WHO,
2006; Okeke et al., 2007).
Moreover, the economic contributions of the pharmaceutical
market as well as the need of such laxly monitored drug
supply chain to serve as a form of affordable ‘system-of-care’
to the general population may post a regulatory dilemma
to health authorities. This will, however, be a double-edged
sword since such healthcare system has indirectly derailed the
stewardship for the judicious use of antibiotics through its
profit-driven model. The pharmaceutical industries in numerous
developing- and developed-nations have been reported to
incentivise health practitioners for pushing the sales of drugs
including antibiotics (Tiong et al., 2016). This is worsened
by the absence of a regulatory framework that separates
prescribing and dispensing to elicit an effective system of
checks and balances in the healthcare systems of this part
of the world. Therefore, rational prescribing of antibiotics
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may be precluded by the monetary gains derived from the
sales of drugs. Likewise, the under-addressed low level of
public awareness pertaining to rational use of antibiotic is an
important causative factor for patient -pressured antibiotic over-
prescribing among doctors as well as the worrisome culture
of antibiotic sharing (Stevenson et al., 1998; Hoffman et al.,
2003; Ellis and Mullan, 2009). It will be an uphill task for
AMS programs to achieve the intended objectives if national
policies and prevailing local sentiments are not aligned with
the concepts of AMS. Needless to say, any push to implement
global AMS initiatives in these countries would first require
strong political will to amend existing policies to make them
AMS-friendly.
High Income Nations are Not
Responding Proactively to the Threat of
Antimicrobial Resistance
The commitment to AMS among the developed nations could
be further improved given their economic and technological
prowess as well as the absence of various adversities faced
by the low- and middle-income nations. These nations have
long recognized antibiotic resistance as a global health threat
although interventions have been gradual which have since
been outpaced by the rate of resistance development and
spread. An intensifying sense of urgency in recent years has
seen numerous recommendations to boost AMS published by
experts in the field, and it is heartening to see some have
been taken forward although others remain unheeded hence
the remaining gaps to be filled. Some governments are still
perceived to be semi-committed to the cause of AMS due to
their reluctance to prioritize the funding of national AMS and
its related initiatives. Policymakers are perhaps mindful of the
significant investment required to sustain AMS programs which
are generally long term projects where positive outcomes are not
guaranteed.
This appears to parallel the insufficient emphasis accorded to
the important AMS-complementing research particularly those
pertaining to bacteriology that may elicit crucial understanding of
resistance mechanisms and patterns of spread. This is exemplified
by several studies that revealed the paltry investment into the
antimicrobial resistance research which constituted merely 3.9%
of the total funding in the UK for infectious disease research
between 1997–2010 whereas barely 1% of research funds across
Europe were channeled into antibiotic research between 2008–
2013 (Bragginton and Piddock, 2014; Head et al., 2014). The
same is true in the United States where the US National Institute
of Health allocated a meager 1.2% of its total research grant
for antimicrobial resistance-related research between 2009–2014
(O’Neill, 2016). This is worrisome primarily when similar level
of apathy was observed among the pharmaceutical companies
toward the research and development of antibiotics. Not only
is the capital investment into this area equally underwhelming
(less than 5% of the total budget between 2003–2013), resources
are continuously being diverted to areas which are deemed
more commercially rewarding (O’Neill, 2016). If this trend
continues, we may be facing an antibiotic apocalypse sooner than
expected.
Disorganized State of Current AMS
The lack of clear definition as to what constitutes an AMS
initiative is likely to have led to an inaccurate estimate of the real
prevalence of worldwide AMS activities (Huttner et al., 2014).
This is attributable to the paucity of a global framework to guide
the articulation of concerted action plans at both international
and national levels, although this also raises the question as to the
feasibility of some of the AMS activities established without the
inputs of field experts.
There is a potential waste of funds due to the risk of non-
validated activities eliciting limited impacts as can be seen in the
implemented programs in some countries (Huttner et al., 2014).
The greater concern, however, is the likelihood of deviation of
hospital-specific AMS precepts from the fundamental rationales
of national guidelines as the onus is placed on individual
centers to formulate their specific measures based on their
own understandings of AMS. This has led to the foreseeable
unsynchronized and/or compartmentalized efforts which is
complicated by the possible risk of concept divergence (Kaki
et al., 2011). For instance, AMS may serve an excuse for
some hospitals to limit antibiotic prescribing where the primary
agenda is to cut cost (MacDougall and Polk, 2005). In light
of this, it is always recommended for the analysis of the
unintended consequence of AMS intervention to be conducted
in conjunction to assessment of its effectiveness. Unfortunately,
AMS feedback mechanisms remain inefficient, and are further
hampered by possible reporting bias where only favorable
outcomes are published in order to ensure continuous funding
(MacDougall and Polk, 2005). All these are pointing to the
disorganized state of current AMS endeavors due to the
absence of standardized AMS policies. Nevertheless, it is worth
noting that overly restrictive guidelines imposed with little
justification may also result in poor voluntary compliance.
Hence there is a need for inputs from all stakeholders (i.e.,
lawmakers, healthcare practitioners, scientists, economists, and
other field experts) in order to establish a consensus-based
practice guideline.
Inter-Sectoral and International
Fragmentation of AMS Implementation
It is irrefutable that the human health sector has become the
subconscious focal point of AMS whereas the inappropriate
use of antibiotics in areas like veterinary medicine and animal
husbandry have often being overlooked. The absence of sectoral
AMS coordination to guide simultaneous implementation
may result in the breeding of resistant pathogens reservoirs
in animals with risk of transmission to humans (Phillips
et al., 2004; Martin et al., 2015). Even if some of the
antibiotics are meant purely for veterinary use, the risk of
development of cross-resistance with those used in humans
cannot be discounted. Regrettably, Salmonella enterica,
E. coli and Enterococcus spp resistant to sulphonamides
and tetracycline in food animals and domestic pets have
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already been documented in South Africa (Mendelson and
Matsoso, 2015). As such, the sectoral fragmentation in AMS
remains a colossal issue to be addressed. Not all is well in
human healthcare sector either. Positive outcomes of AMS
are generally confined to countries with properly–planned and
administered AMS programs such as those in the G7 block
(Canada, France, Germany, Italy, Japan, UK, and USA; WHO,
2014, 2015; O’Neill, 2016). These countries are commendable
for their proactive stance although it is immediately apparent
that antibiotic resistance is a worldwide crisis which cannot be
tackled by the efforts of few countries alone. While ‘success’ in the
context of AMS-guided action plans remains difficult to define
(hence beyond the scope of this article), it is safe to conclude
that localized successes will have limited impact on a global
scale. With the ease of global travel and trade, localized AMS
achievements could be undone by the resistance transmitted
from regions known to be ‘hotspots.’ In other words, common
AMS policies between participating countries would be rendered
ineffective in the absence of concurrent implementation across-
the-board at the point of contact.
The Way Forward
It is particularly welcoming to see the excellent recommendations
made in the recently published Review on Antimicrobial
Resistance for tackling antimicrobial resistance in a global
manner (O’Neill, 2016). The authors of this article agreed
with the published report that the fight against antimicrobial
resistant-infections entails the forging of an international
coalition involving all countries. A comprehensive framework
for national plans has been established under WHO but we
opine that it should be made legally binding in its push for
simultaneous implementation across all sectors among member
states whilst steering all toward a common precept. This is
in-line with the integrative/collaborative approach advocated
through the One Health concept which is receiving increasing
attention lately (Mills, 2014). High income nations on the
other hand, should assume a more proactive role and to take
lead in administering the action plans internationally through
the sharing of expertise, experience, and resources. In this
context, it is paramount to expand the coverage of effective
AMS initiatives to all LMICs in which implementation has
proved problematic thus far due to the presence of many
country-specific limiting factors. Attention should be paid in
intensifying efforts in these nations whose populace made up
approximately two third of world population, where a drug-
resistant outbreak would most certainly set off far-reaching
health and economic implications. The Fleming Fund is
certainly a move in the right direction in providing impetus
to improve drug-resistance infections surveillance in these
countries (O’Neill, 2016). A global AMS initiatives fund with
mandatory reporting of process indicators should also be
considered to spur AMS programs particularly among the
LMICs. Nonetheless, the immediate agenda for the international
communities would be the identification of sources of sustainable
funding in order to ensure the continuum of AMS initiatives
worldwide.
It is encouraging to see the recent efforts in strengthening
AMS among some of the emerging economies. The South African
Antibiotic Stewardship Programme (SAASP) and Vietnam
Resistance (VINARES) are two initiatives to be emulated by
developing nations faced with the many adversities in combating
antimicrobial resistance (Nguyen et al., 2013; Mendelson and
Matsoso, 2015). Both SAASP and VINARES projects represent
exemplary models of policy-guided national action plans
formulated based on situational analysis, taking into account
the resource-limiting environment of developing nations. It is
important to note that, a dynamic approach should be taken
where tweaking of AMS programs may be required from time
to time in order to tailor the right initiatives to the local
sentiments.
CONCLUSION
We have certainly come a long way with our efforts in
combating the scourge of antimicrobial resistance through AMS.
Nevertheless, uncertainty remains as to how widespread is the
global adoption of AMS in order to avert an impending world
disaster. From a global perspective, AMS has yet to attain its
intended objective in tackling worldwide spread of antimicrobial
resistance. Hence, we should acknowledge that there are still gaps
to be bridged especially in ensuring that future initiatives will be
made more feasible, robust, and multi-faceted for wider adoption
across different geographical and socio-economic settings. That
being said, much time has been spent strategizing and it is time
we translate these strategies into actions before the window of
opportunity is lost.
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